REGN

Regeneron Pharmaceuticals
D

REGN

600.25
USD
-7.69
(-1.27%)
قبل الجلسة·609.05USD+8.80(+1.47%)
حجم التداول
10,695
الربح لكل سهم
45
العائد الربحي
0.6
P/E
15
حجم السوق
62,925,435,397
أصول ذات صلة الأخبار المقالات
المزيد

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.